aminoimidazole carboxamide has been researched along with T-Cell Lymphoma in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Asnafi, V; Bost, F; Hagenbeek, T; Imbert, V; Lounnas, N; Michiels, JF; Nebout, M; Peyron, JF; Pontier-Bres, R; Reverso, J; Rosilio, C; Sahra, IB; Spits, H | 1 |
1 other study(ies) available for aminoimidazole carboxamide and T-Cell Lymphoma
Article | Year |
---|---|
The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-deficient T cell lymphomas and human T-ALL/T-LL cancer cells.
Topics: Alleles; Aminoimidazole Carboxamide; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; Jurkat Cells; Lymphoma, T-Cell; Metformin; Mice; Mice, Nude; Neoplasm Transplantation; Phenformin; PTEN Phosphohydrolase; Ribonucleotides; Transgenes | 2013 |